| Name | Title | Contact Details |
|---|
Payfare is a global FinTech company offering mobile banking, instant payment and loyalty-reward solutions for today`s workforce. Payfare`s financial technology platform is providing financial inclusion and empowerment to millions of next-generation workers around the globe with a full-service mobile bank account and debit card with instant access to their earnings and relevant cash-back rewards. Payfare was founded in 2015 by fintech entrepreneurs and a senior management team with unparalleled experience in the banking, payment card and financial technology sectors. Payfare is backed by major investors and financial institutions around the world. The company is headquartered in Toronto, Canada. Some of the world`s largest on-demand economy platforms including Uber, Lyft, DoorDash and DiDi trust Payfare to pay their workers.
Kalmar is a Finland-based company that designs and distributes open automation systems for cargo container handling applications in ports and terminals.
RESRG Automotive is a global automotive supplier formed from the merger of Rehau Automotive and SRG Global Automotive, officially launched in April 2025. Headquartered in Troy, Michigan, with a European base in Rehau, Germany, the company operates 22 production sites across multiple countries, including Germany, France, and India. With a workforce of around 10,000 employees, RESRG projects pro-forma sales of €1.7 billion. The company specializes in polymer-based exterior and functional systems, offering products such as bumpers, grilles, lamp bezels, and roof panels. RESRG employs advanced manufacturing processes like injection molding and galvanizing, focusing on combining aesthetic appeal with functional performance. The company aims to partner with leading automakers to provide innovative solutions in automotive design and technology.
One Community Bank is a locally owned community bank serving south-central Wisconsin. It was formed from the merger of Oregon Community Bank and McFarland State Bank and now serves 19 communities, including Oregon, Middleton, Sun Prairie, and Wausau. The bank is dedicated to providing personalized service and investing in local communities. The bank offers a wide range of personal and business banking services. Personal banking products include checking and savings accounts, certificates of deposit, money market accounts, mortgages, and consumer loans for various needs. For businesses, One Community Bank provides checking accounts with no minimum balance or monthly fees, interest-bearing options, and dedicated local bankers to assist with banking operations. One Community Bank emphasizes a client-centric approach, combining traditional banking with modern digital solutions like online and mobile banking. The bank is committed to community engagement through volunteerism and support for local nonprofits, reflecting its dedication to the well-being of the communities it serves.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.